Skip to main content

Table 1 Demographics and clinical characteristics of patients with HCV genotype 1b treated with elbasvir/grazoprevir

From: Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection

 Total population
N = 3614
Age, n (%) years
 18–652203 (61.0)
 > 651411 (39.0)
Race/ethnicity, n (%)
 Black2199 (60.9)
 White1099 (30.4)
 Other60 (1.7)
 Hispanic104 (2.9)
 Unknown152 (4.2)
Male, n (%)3516 (97.3)
BMI, kg/m2, n (%)a
 < 251176 (32.5)
 25 to < 301323 (36.6)
 ≥ 301086 (30.1)
 Unknown29 (0.8)
Baseline HCV RNA, n (%)
 < 800,000 IU/mL1106 (30.6)
 ≥ 800,000 IU/mL2347 (64.9)
 Unknown161 (4.5)
Platelets count, n (%)
 < 100,000 cells/µL133 (3.7)
 ≥ 100,000 cells/µL3180 (88.0)
 Missing301 (8.3)
HCV treatment history, n (%)
 Treatment naive3245 (89.8)
 Treatment experiencedb369 (10.2)
Treatment regimens, n (%)= 3584
 EBR/GZR for 12 weeks3201 (89.3)
  Treatment-naive2883 (80.4)
  Treatment-experienced318 (8.9)
 EBR/GZR for 8 weeks240 (6.7)
  Treatment-naive218 (6.1)
  Treatment-experienced22 (0.6)
 EBR/GZR + RBV (8–16 weeks)62 (1.7)
 Other81 (2.3)
  1. BMI body mass index, EBR/GZR elbasvir/grazoprevir, HCV hepatitis C virus
  2. aChi-square p < 0.05
  3. bHCV treatment experience was defined as prior use of any interferon-based regimen (with or without ribavirin), the first-generation protease inhibitors boceprevir or telaprevir, or simeprevir or sofosbuvir